From the Journals

Benign MS is real in small minority of patients


 

FROM THE JOURNAL OF NEUROLOGY, NEUROSURGERY & PSYCHIATRY

Nearly 3% of patients with multiple sclerosis (MS) are estimated to have a truly benign course of disease over at least 15 years without the use of disease-modifying therapy, based on findings from a U.K. population-based study that also showed how poorly benign disease tracks with disability measures and lacks agreement between patients and physicians.

A diagnosis form says multiple sclerosis. designer491/Thinkstock

“The study of the individuals with extremely favorable outcomes may uncover insights about disease pathogenesis or repair. However, the insensitivity of EDSS [Expanded Disability Status Scale]–based definitions of benign MS and the discrepancy between patient and clinician perception of benign MS undermine use of the term ‘benign’ in the clinical setting,” Emma Clare Tallantyre, MD, of Cardiff (Wales) University, and her colleagues wrote in the Journal of Neurology, Neurosurgery & Psychiatry.

Dr. Tallantyre and her colleagues found that, of 1,049 patients with disease duration longer than 15 years, 200 had a recent EDSS score of less than 4.0. Of those 200, 60 were clinically assessed and 9 (15%) were found to have truly benign MS, defined as having an EDSS less than 3.0 and having no significant fatigue, mood disturbance, cognitive impairment, or disruption to employment in the absence of disease-modifying therapy at least 15 years after symptom onset.

The investigators extrapolated these data to estimate that 30 patients in the study population of 1,049 had truly benign MS, for a prevalence of 2.9%. However, of the 60 patients who were clinically assessed, 39 thought they had benign MS based on the lay definition provided: “When referring to illness, ‘benign’ usually means a condition which has little or no harmful effects on a person. There are no complications and there is a good outcome or prognosis.”

Patients who self-reported benign MS had significantly lower EDSS scores, fewer depressive symptoms, lower fatigue severity, and lower reported MS impact than did patients who did not report benign MS. “Self-reported benign MS status showed poor agreement with our composite definition of benign MS status and only fair agreement with EDSS-based definitions of benign MS status,” the investigators wrote.

SOURCE: Tallantyre EC et al. J Neurol Neurosurg Psychiatry. 2018 Sep 3. doi: 10.1136/jnnp-2018-318802.

Recommended Reading

Lipid Metabolism May Be a Therapeutic Target in MS
MDedge Neurology
A Rational Approach to Starting, Stopping, and Switching DMTs
MDedge Neurology
Investigators Describe the MS Prodrome
MDedge Neurology
Fitbit Flex is feasible, provides nuanced step count data in MS patients
MDedge Neurology
Conference News Roundup—European Academy of Neurology
MDedge Neurology
Treatment of relapsing progressive MS may reduce disability progression
MDedge Neurology
Aspirin May Be an Effective Pretreatment for Exercise in Patients With MS
MDedge Neurology
New MS criteria may create more false positives
MDedge Neurology
New MS subtype shows absence of cerebral white matter demyelination
MDedge Neurology
Serum Nf-L shows promise as biomarker for BMT response in MS
MDedge Neurology